AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00878228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol 12 mcg
Description: Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg
Description: Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100 mcg
Description: Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg
Description: Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg
Description: Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg
Description: Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 500 mcg
Description: Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
Study NCT01845025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match formoterol one inhalation twice daily via dry powder inhaler
Study NCT02760602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV
Study NCT02760602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study NCT00703807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
Study NCT00703807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
Study NCT01580475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training - detraining - retraining
Description: Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
Study NCT00404768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK221149A
Description: 6mg/h and 12 mg/h
Study NCT00404768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo to Drug
Study NCT02606786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stabilization exercises
Description: The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
Study NCT03461289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
Study NCT03397485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Growing milk
Description: Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
Study NCT03397485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified milk
Description: Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
Study NCT00668525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
Study NCT00668525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration, once daily dosing for 8 weeks
Study NCT00668525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram high dose, oral administration, once daily dosing for 8 weeks
Study NCT01678846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good School Toolkit
Description: The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
Study NCT02021812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Study NCT02113748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill walking training
Description: Walk on a treadmill with a negative inclination.
Study NCT02113748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking training
Description: Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
Study NCT02211495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEKO device
Description: Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
Study NCT02211495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Medical Therapy
Description: Seen in outpatient clinic for wound care and ongoing advice
Study NCT02211495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Seen in outpatient clinic for wound care and ongoing advice
Study NCT00883428 — intervention group
Intervention type: OTHER
Intervention: Set of questionnaires
Description: A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
Study NCT02666911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4D Ultrasound
Description: Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
Study NCT02666911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D ultrasound
Description: Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
Study NCT02077322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silastic Spacer
Description: The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
Study NCT02077322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merocel Spacer
Description: The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
Study NCT03798561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN008 TG
Description: ASN008 TG
Study NCT03798561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TG
Description: Placebo TG
Study NCT03671369 — intervention group
Intervention type: OTHER
Intervention: Safety data collection (following routine vaccination) by a continuous surveillance method.
Description: This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS.
Study NCT04385030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY
Description: The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
Study NCT04385030 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY
Description: The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
Study NCT02583750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OGTT after deprived sleep first
Description: Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
Study NCT02583750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OGTT after sufficient sleep first
Description: Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
Study NCT02060708 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HD-tDCS
Description: HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
Study NCT00184054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO)
Description: Arsenic Trioxide .25 mg/kg/day
Study NCT00184054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid 1000 mg every other day for 25 days
Study NCT01757691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03406923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy-psychosocial support
Description: The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
Study NCT04031690 — intervention group
Intervention type: OTHER
Intervention: Patient Quality of Life Questionnaires
Description: Quality of life measurement at D0, M6 and M12 via the SF-36
Study NCT04051307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL
Description: Peptide vaccination
Study NCT04051307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL
Description: Peptide vaccination
Study NCT01812993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilatory treatment with auto-BPAP
Study NCT03497130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin care regimen
Description: These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
Study NCT00109512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-56418 (GnRH antagonist)
Study NCT04484662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Potted Mint Plants
Description: We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
Study NCT04693247 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EQ103
Description: Refraction device
Study NCT04693247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EQ103
Description: Refraction device
Study NCT02076672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artichoke WPC
Description: Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
Study NCT01188798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Study NCT01188798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Study NCT02797366 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Proton radiotherapy
Study NCT03562780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fortolin Tab 500mg
Description: Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
Study NCT03562780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol Caplet 500mg
Description: Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
Study NCT02711748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation using manual defibrillator
Study NCT02711748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation
Description: CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
Study NCT01625078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement and use of Baska mask
Description: Use of Baska mask as a supraglottic airway during general anesthesia
Study NCT04535479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
Study NCT03005574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSW-HP
Description: TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
Study NCT03005574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TSW-T
Description: Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
Study NCT02276833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-articular space injection of SVF
Description: intra-articular injection of autologous adipose SVF derived in the same surgical procedure
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Perception Threshold Tracking (PTT)
Description: low-current electrical stimulation of both large- and small nerve fibers.
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Axon-flair mediated respons
Description: Laser-doppler examination of small blood vessels in the peripheral skin.
Study NCT01073072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: 4 measurements of heart rate.
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing (QST)
Description: Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
Study NCT01073072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technique Tutomesh®
Description: Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood pressure and transcutaneous oxygen tension
Description: Ankle/brachial index, toe/brachial index, TcpO2.
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Questionnaires for detecting painful neuropathy
Study NCT04078516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal Confocal Microscopy /CCM)
Description: Confocal microscopy of the cornea measuring NBD, NFD, NFL
Study NCT02441816 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Study NCT02441816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extend Treatment
Description: In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
Study NCT02502383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION PAC
Description: School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
Study NCT02502383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication with parents
Description: A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.